For research use only. Not for therapeutic Use.
DPTIP is a potent brain penetrant neutral sphingomyelinase 2 (N-SMase 2) inhibitor (exosome inhibitor), with an IC50 of 30 nM[1][2].
DPTIP blocks EV secretion in a dose dependent manner (0.03-30 μM), and at 30 μM, this compound could decrease exosome release by 50% in astrocytes[2].
DPTIP potently (10 mg/kg IP) inhibits IL-1β-induced astrocyte-derived EV release[1].
| Catalog Number | I026509 |
| CAS Number | 351353-48-5 |
| Synonyms | 2,6-dimethoxy-4-(4-phenyl-5-thiophen-2-yl-1H-imidazol-2-yl)phenol |
| Molecular Formula | C21H18N2O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C21H18N2O3S/c1-25-15-11-14(12-16(26-2)20(15)24)21-22-18(13-7-4-3-5-8-13)19(23-21)17-9-6-10-27-17/h3-12,24H,1-2H3,(H,22,23) |
| InChIKey | JMXVHYPSBANVAQ-UHFFFAOYSA-N |
| SMILES | COC1=CC(=CC(=C1O)OC)C2=NC(=C(N2)C3=CC=CS3)C4=CC=CC=C4 |
| Reference | [1]. Camilo Rojas, et al. DPTIP, a newly identified potent brain penetrant neutral sphingomyelinase 2 inhibitor, regulates astrocyte-peripheral immune communication following brain inflammation. Sci Rep. 2018 Dec 7;8(1):17715. [2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. |
